Dextropropoxyphene is dead? Long live....
Keywords:
Dextropropoxyphene, withdrawn,Abstract
On 20 April 2011, the Medicines Control Council (MCC) announced its decision to withdraw all dextropropoxyphene-(DPP-) containing products from the South African market within three months, because of stated safety risks and an insufficiently weighted risk-benefit profile. These risks refer to dose-related cardiac conduction abnormalities associated with QT prolongation, provoked by the main metabolite of DPP, norpropoxyphene. Cases of fatal arrhythmias have been described.Downloads
Issue
Section
Guest Editorial
License
By submitting manuscripts to SAJAA, authors of original articles are assigning copyright to the SA Society of Anaesthesiologists. Authors may use their own work after publication without written permission, provided they acknowledge the original source. Individuals and academic institutions may freely copy and distribute articles published in SAJAA for educational and research purposes without obtaining permission.
The work is licensed under a Creative Commons Attribution-Non-Commercial Works 4.0 South Africa License. The SAJAA does not hold itself responsible for statements made by the authors.